Literature DB >> 26170099

Understanding the risk for infection in patients with neutropenia.

Jean A Klastersky1, Anne-Pascale Meert2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26170099     DOI: 10.1007/s00134-015-3965-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  18 in total

1.  Identification of educational and infrastructural barriers to prompt antibiotic delivery in febrile neutropenia: a quality improvement initiative.

Authors:  Erica Burry; Angela Punnett; Ashley Mehta; Jennifer Thull-Freedman; Lisa Robinson; Sumit Gupta
Journal:  Pediatr Blood Cancer       Date:  2011-12-06       Impact factor: 3.167

Review 2.  Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.

Authors:  John R Wingard; Mohamed Elmongy
Journal:  Crit Rev Oncol Hematol       Date:  2009-02-23       Impact factor: 6.312

3.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

4.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

5.  Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.

Authors:  Shin Ahn; Yoon-Seon Lee; Yun-Hee Chun; In-Ho Kwon; Won Kim; Kyung Soo Lim; Tae Won Kim; Kyoo-Hyung Lee
Journal:  Support Care Cancer       Date:  2010-06-16       Impact factor: 3.603

6.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

Review 7.  Febrile neutropenia: a critical review of the initial management.

Authors:  Jean Klastersky; Ahmad Awada; Mariane Paesmans; Mickael Aoun
Journal:  Crit Rev Oncol Hematol       Date:  2010-04-21       Impact factor: 6.312

8.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

Authors:  Catherine Cordonnier; Cécile Pautas; Sébastien Maury; Anne Vekhoff; Hassan Farhat; Felipe Suarez; Nathalie Dhédin; Francoise Isnard; Lionel Ades; Frédérique Kuhnowski; Françoise Foulet; Mathieu Kuentz; Patrick Maison; Stéphane Bretagne; Michaël Schwarzinger
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

9.  De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.

Authors:  Djamel Mokart; Géraldine Slehofer; Jérôme Lambert; Antoine Sannini; Laurent Chow-Chine; Jean-Paul Brun; Pierre Berger; Ségolène Duran; Marion Faucher; Jean-Louis Blache; Colombe Saillard; Norbert Vey; Marc Leone
Journal:  Intensive Care Med       Date:  2014-01       Impact factor: 17.440

Review 10.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

View more
  3 in total

1.  The High Prevalence of Functional Complement Defects Induced by Chemotherapy.

Authors:  Mischa P Keizer; Angela M Kamp; Cathelijn Aarts; Judy Geisler; Huib N Caron; Marianne D van de Wetering; Diana Wouters; Taco W Kuijpers
Journal:  Front Immunol       Date:  2016-10-17       Impact factor: 7.561

Review 2.  Empirical antimicrobial treatment in haemato-/oncological patients with neutropenic sepsis.

Authors:  Matthias Gerhard Vossen; Christopher Milacek; Florian Thalhammer
Journal:  ESMO Open       Date:  2018-06-13

Review 3.  [Psychopharmacotherapy during the COVID-19 pandemic].

Authors:  J Seifert; J Heck; G Eckermann; M Singer; S Bleich; R Grohmann; S Toto
Journal:  Nervenarzt       Date:  2020-07       Impact factor: 1.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.